Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with relapsed or refractory disease who are participating in a Phase 1b/2 trial. These findings were announced in an oral presentation, “Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma,” at the recent 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program,…
You must be logged in to read/download the full post.
The post JNJ-4528 Continues to Show Strong, Durable Responses in Trial appeared first on BioNewsFeeds.